[Update on PCSK9 Inhibition]

Overview

Journal Herz

Specialty Cardiology & Vascular Diseases

Date 2022 Apr 21

PMID 35445838

Authors

Julius L Katzmann

Florian Custodis

Stephan H Schirmer

Ulrich Laufs

Affiliations

Soon will be listed here.

Abstract

Lowering of low-density lipoprotein (LDL) cholesterol represents one of the most effective interventions in cardiovascular prevention. Besides the oral treatment with statins, ezetimibe and bempedoic acid, subcutaneously administered inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) have been established as further cornerstones of lipid-lowering treatment. The antibodies evolocumab and alirocumab are administered subcutaneously every 2-4 weeks and lower LDL cholesterol by around 60%, independent of pre-treatment with very good tolerability. Both drugs successfully reduced cardiovascular endpoints in large outcome trials. A novel principle of PCSK9 inhibition is RNA interference, which is exploited by the novel compound inclisiran. Inclisiran is a double-stranded modified RNA molecule, which neutralizes the mRNA of PCSK9 and thus inhibits PCSK9 protein synthesis intracellularly. Inclisiran only needs to be administered every 6 months. The cardiovascular outcome trial ORION‑4 is currently ongoing. In Germany, prescription of PCSK9 inhibitors is regulated by the decision of the Federal Joint Committee. Novel strategies to inhibit PCSK9 function are under development and include orally available drugs and animal experiment concepts on gene editing, which are in different states of evaluation.

References

Ference B, Ginsberg H, Graham I, Ray K, Packard C, Bruckert E . Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32):2459-2472. PMC: 5837225. DOI: 10.1093/eurheartj/ehx144. View

Katzmann J, Mahfoud F, Bohm M, Schulz M, Laufs U . Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk. Patient Prefer Adherence. 2018; 13:9-19. PMC: 6302826. DOI: 10.2147/PPA.S182765. View

Seidah N, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin S, Stifani S . The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003; 100(3):928-33. PMC: 298703. DOI: 10.1073/pnas.0335507100. View

Abifadel M, Varret M, Rabes J, Allard D, Ouguerram K, Devillers M . Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34(2):154-6. DOI: 10.1038/ng1161. View

Cohen J, Boerwinkle E, Mosley Jr T, Hobbs H . Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006; 354(12):1264-72. DOI: 10.1056/NEJMoa054013. View

Ference B, Robinson J, Brook R, Catapano A, Chapman M, Neff D . Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J Med. 2016; 375(22):2144-2153. DOI: 10.1056/NEJMoa1604304. View

Lagace T, Curtis D, Garuti R, McNutt M, Park S, Prather H . Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006; 116(11):2995-3005. PMC: 1626117. DOI: 10.1172/JCI29383. View

Glerup S, Schulz R, Laufs U, Schluter K . Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease. Basic Res Cardiol. 2017; 112(3):32. PMC: 5403857. DOI: 10.1007/s00395-017-0619-0. View

Ridker P, Tardif J, Amarenco P, Duggan W, Glynn R, Jukema J . Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med. 2017; 376(16):1517-1526. DOI: 10.1056/NEJMoa1614062. View

10.

Sabatine M . PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 2018; 16(3):155-165. DOI: 10.1038/s41569-018-0107-8. View

11.

Katzmann J, Gouni-Berthold I, Laufs U . PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects. Front Physiol. 2020; 11:595819. PMC: 7701092. DOI: 10.3389/fphys.2020.595819. View

12.

Sabatine M, Giugliano R, Keech A, Honarpour N, Wiviott S, Murphy S . Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017; 376(18):1713-1722. DOI: 10.1056/NEJMoa1615664. View

13.

Giugliano R, Pedersen T, Park J, De Ferrari G, Gaciong Z, Ceska R . Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017; 390(10106):1962-1971. DOI: 10.1016/S0140-6736(17)32290-0. View

14.

Giugliano R, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E . Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017; 377(7):633-643. DOI: 10.1056/NEJMoa1701131. View

15.

Gencer B, Mach F, Guo J, Im K, Ruzza A, Wang H . Cognition After Lowering LDL-Cholesterol With Evolocumab. J Am Coll Cardiol. 2020; 75(18):2283-2293. DOI: 10.1016/j.jacc.2020.03.039. View

16.

Marston N, Kamanu F, Nordio F, Gurmu Y, Roselli C, Sever P . Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial. Circulation. 2019; 141(8):616-623. PMC: 8058781. DOI: 10.1161/CIRCULATIONAHA.119.043805. View

17.

Sabatine M, De Ferrari G, Giugliano R, Huber K, Lewis B, Ferreira J . Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER. Circulation. 2018; 138(8):756-766. DOI: 10.1161/CIRCULATIONAHA.118.034309. View

18.

Bonaca M, Nault P, Giugliano R, Keech A, Lira Pineda A, Kanevsky E . Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2017; 137(4):338-350. DOI: 10.1161/CIRCULATIONAHA.117.032235. View

19.

Bohula E, Giugliano R, Leiter L, Verma S, Park J, Sever P . Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation. 2018; 138(2):131-140. DOI: 10.1161/CIRCULATIONAHA.118.034032. View

20.

Charytan D, Sabatine M, Pedersen T, Im K, Park J, Lira Pineda A . Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. J Am Coll Cardiol. 2019; 73(23):2961-2970. DOI: 10.1016/j.jacc.2019.03.513. View